(Q35547264)

8 August 2017

1 reference

title

Emerging technologies that overcome biological barriers for therapeutic protein delivery (English)

1 reference

8 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

16 March 2024

2

Randall J. Mrsny

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14519072

16 March 2024

author name string

Ann L. Daugherty

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14519072

16 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/14712598.3.7.1071

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Expert Opinion on Biological Therapy

16 March 2024

published in

1 reference

8 August 2017

volume

3

1 reference

8 August 2017

issue

7

1 reference

8 August 2017

page(s)

1071-1081

1 reference

Pharmacogenetics and future drug development and delivery

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Selected advances in drug delivery and tissue engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Emerging protein delivery methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Macromolecular versus small-molecule therapeutics: drug discovery, development and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Image-guided robotic delivery system for precise placement of therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Acute pancreatitis attributed to the use of interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Crystalline monoclonal antibodies for subcutaneous delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Review on the systemic delivery of insulin via the ocular route

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Nasal drug delivery: new developments and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Novel mechanisms and devices to enable successful transdermal drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Developments in the area of bioadhesive drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Drug delivery across the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Current status and future prospects of transdermal drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Iontophoresis: electrorepulsion and electroosmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Transdermal therapy and diagnosis by iontophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Ultrasound-mediated transdermal protein delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Microfabricated microneedles for gene and drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Microchip technology in drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Synergistic effect of enhancers for transdermal drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

The ascent of pulmonary drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Bioengineering of therapeutic aerosols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Inhalation delivery of proteins from ethanol suspensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Transcellular uptake mechanisms of the intestinal epithelial barrier Part one.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Plasma membrane components of adherens junctions (Review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Oral drug absorption enhancement by chitosan and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Membrane traffic in polarized epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

The potential use of receptor-mediated endocytosis for oral drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Gastrointestinal uptake of biodegradable microparticles: effect of particle size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Targeting approaches to oral drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Delivery of peptides and proteins through the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Drug and gene targeting to the brain with molecular Trojan horses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Local treatment of brain tumors with targeted chimera cytotoxic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Targeted drug delivery to the brain; (blood-brain barrier, efflux, endothelium, biological transport).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

The role of the transferrin-transferrin-receptor system in drug delivery and targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Effects of Human Insulin on Insulin Binding Antibody Production in Nondiabetic Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

RANDOMIZED CONTROLLED TRIAL OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR THE TREATMENT OF CHRONIC HEPATITIS C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

A controlled-release microchip

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1071

Transforming growth factor beta-3 crystals as reservoirs for slow release of active TGF-beta3

21 January 2018

10

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b

16 March 2024

12

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease

16 March 2024

13

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Incidence and associated factors of neutralizing anti-interferon antibodies among chronic hepatitis C patients treated with interferon in Taiwan

16 March 2024

14

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C

16 March 2024

16

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients

16 March 2024

17

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta

16 March 2024

18

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2

16 March 2024

19

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Transdermal drug delivery: overcoming the skin's barrier function

16 March 2024

24

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Effect of ultrasound application on skin metabolism of prednisolone 21-acetate

16 March 2024

34

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Combined effect of low-frequency ultrasound and iontophoresis: applications for transdermal heparin delivery

16 March 2024

38

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Synergistic effect of electric field and ultrasound on transdermal transport

16 March 2024

39

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Medihaler therapy for bronchial asthma; a new type of aerosol therapy

16 March 2024

41

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Delivery of biotherapeutics by inhalation aerosol.

16 March 2024

43

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Large porous particles for pulmonary drug delivery

16 March 2024

48

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Regulation of the intestinal epithelial paracellular barrier

16 March 2024

50

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Enhancing paracellular permeability by modulating epithelial tight junctions

16 March 2024

53

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Oral delivery of biologically active parathyroid hormone

16 March 2024

59

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Nanosphere based oral insulin delivery

16 March 2024

64

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Polymeric system for dual growth factor delivery

16 March 2024

72

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

16 March 2024

Zhonghua yi xue za zhi

73

47

313

HO LT

1991

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha

16 March 2024

76

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1071

16 March 2024

Identifiers

1 reference

8 August 2017

1 reference